TrialAntimicrobial agents and chemotherapy2024

First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus.

Xiao-Jian Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.